Bioactivity and safety of IL13Rα2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4062-4072

  Brown, Christine E ^a   Badie, Behnam ^a   Barish, Michael E ^a   Weng, Lihong ^a   Ostberg, Julie R ^a   Chang, Wen Chung ^a   Naranjo, Araceli ^a   Starr, Renate ^a   Wagner, Jamie ^a   Wright, Christine ^a   Zhai, Yubo ^a   Bading, James R ^a   Ressler, Julie A ^a   Portnow, Jana ^a   D'Apuzzo, Massimo ^a   Forman, Stephen J ^a   Jensen, Michael C ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 13 RECEPTOR ALPHA2; MESSENGER RNA; HLA ANTIGEN; IL13-ZETAKINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CRANIOTOMY; CYTOTOXIC T LYMPHOCYTE; ENCEPHALITIS; FATIGUE; FEASIBILITY STUDY; FIRST IN HUMAN STUDY; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN TISSUE; LEUKOPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; RETREATMENT; SHUFFLING GAIT; TONGUE DISEASE; TUMOR NECROSIS; TUMOR RECURRENCE; AGED; BRAIN; BRAIN NEOPLASMS; CHEMISTRY; CYTOLOGY; FEMALE; GLIOMA; IMMUNOLOGY; INFLAMMATION; MALE; MIDDLE AGED; PATHOLOGY; PATIENT SAFETY; PROCEDURES; RECURRENT DISEASE; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEASIBILITY STUDIES; FEMALE; GLIOBLASTOMA; GLIOMA; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PATIENT SAFETY; PILOT PROJECTS; RECEPTORS, ANTIGEN, T-CELL; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942908170     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0428     Document Type: Article

References (32)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14:v1-49.
2. Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front Oncol 2013;3:275.
3. Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 2010; 16:474-85.
4. Sampson JH, Choi BD, Sanchez-Perez L, Suryadevara CM, Snyder DJ, Flores CT, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumorantigen loss. Clin Cancer Res 2014;20:972-84.
5. Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D'Apuzzo M, et al. Stem-like tumor-initiating cells isolated from il13ralpha2 expressing gliomas are targeted and killed by IL13-Zetakine-redirected T cells. Clin Cancer Res 2012;18:2199-209.
6. Chow KK, Naik S, Kakarla S, Brawley VS, Shaffer DR, Yi Z, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther 2013;21:629-37.
7. Brown CE, Vishwanath RP, Aguilar B, Starr R, Najbauer J, Aboody KS, et al. Tumor-derived chemokineMCP-1/CCL2 is sufficient formediating tumor tropism of adoptively transferred T cells. J Immunol 2007; 179:3332-41.
8. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, et al. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res 2010;16:4892-8.
9. Yaghoubi SS, Jensen MC, Satyamurthy N, Budhiraja S, Paik D, Czernin J, et al. Noninvasive detection of therapeutic cytolytic T cells with 18F-FHBG PET in a patient with glioma. Nat Clin Pract Oncol 2009;6:53-8.
10. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014;123: 2625-35.
11. Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J 2014;20: 112-8.
12. Brown CE, Warden CD, Starr R, Deng X, Badie B, Yuan YC, et al. Glioma IL13Ralpha2 is associated with mesenchymal signature gene expression and poor patient prognosis. PLoS One 2013;8:e77769.
13. Thaci B, Brown CE, Binello E, Werbaneth K, Sampath P, Sengupta S. Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy. Neuro Oncol 2014;16:1304-12.
14. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res 2008;14:199-208.
15. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999;5:985-90.
16. He CH, Lee CG, Dela Cruz CS, Lee CM, Zhou Y, Ahangari F, et al. Chitinase 3-like 1 regulates cellular and tissue responses via IL-13 receptor alpha2. Cell Rep 2013;4:830-41.
17. Fichtner-Feigl S, Terabe M, Kitani A, Young CA, Fuss I, Geissler EK, et al. Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res 2008;68:3467-75.
18. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin- 13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res 2007;67:7983-6.
19. Joshi BH, Puri RA, Leland P, Varricchio F, Gupta G, Kocak M, et al. Identification of interleukin-13 receptor alpha2 chain overexpression in situ in high-grade diffusely infiltrative pediatric brainstem glioma. Neuro Oncol 2008;10:265-74.
20. Kawakami M, Kawakami K, Takahashi S, Abe M, Puri RK. Analysis of interleukin-13 receptor alpha2 expression in human pediatric brain tumors. Cancer 2004;101:1036-42.
21. Iwami K, Shimato S, OhnoM, Okada H, Nakahara N, Sato Y, et al. Peptidepulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A-24/A-02 allele. Cytotherapy 2012;14:733-42.
22. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, et al. Direct intracerebral delivery of cintredekin besudotox (IL13- PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25: 837-44.
23. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res 2004;64: 9160-6.
24. Debinski W, Thompson JP. Retargeting interleukin 13 for radioimmunodetection and radioimmunotherapy of human high-grade gliomas. Clin Cancer Res 1999;5:3143s-7s.
25. Jensen MC, Clarke P, Tan G, Wright C, Chung-Chang W, Clark TN, et al. Human T lymphocyte genetic modification with naked DNA. J Mol Ther 2000;1:49-55.
26. Davila ML, Bouhassira DC, Park JH, Curran KJ, Smith EL, Pegram HJ, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol 2014;99:361-71.
27. Torikai H, Reik A, Liu PQ, Zhou Y, Zhang L, Maiti S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 2012;119:5697-705.
28. Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 2011;13:324-33.
29. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9.
30. Hegde M, Corder A, Chow KK, Mukherjee M, Ashoori A, Kew Y, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther 2013;21:2087-101.
31. Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010;16:1245-56.
32. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007; 15:825-33.